X0306 4 2020-09-28 1 0001510487 Principia Biopharma Inc. PRNB 0001751719 Goldstein David M C/O PRINCIPIA BIOPHARMA INC. 220 E. GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Scientific Officer Common Stock 2020-09-28 4 U 0 31826 100.00 D 0 D Employee Stock Option (right to buy) 3.1794 2020-09-28 4 D 0 12960 D 2024-06-26 Common Stock 12960 0 D Employee Stock Option (right to buy) 4.7236 2020-09-28 4 D 0 13210 D 2024-12-25 Common Stock 13210 0 D Employee Stock Option (right to buy) 4.7236 2020-09-28 4 D 0 8807 D 2024-12-25 Common Stock 8807 0 D Employee Stock Option (right to buy) 4.9961 2020-09-28 4 D 0 15412 D 2025-07-20 Common Stock 15412 0 D Employee Stock Option (right to buy) 4.9961 2020-09-28 4 D 0 22017 D 2026-03-14 Common Stock 22017 0 D Employee Stock Option (right to buy) 7.2671 2020-09-28 4 D 0 34677 D 2027-12-13 Common Stock 34677 0 D Employee Stock Option (right to buy) 11.3549 2020-09-28 4 D 0 44034 D 2028-08-23 Common Stock 44034 0 D Employee Stock Option (right to buy) 35.42 2020-09-28 4 D 0 60000 D 2029-02-28 Common Stock 60000 0 D Employee Stock Option (right to buy) 67.31 2020-09-28 4 D 0 75000 D 2030-03-04 Common Stock 75000 0 D Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes. Includes 87 shares acquired under the Employment Stock Purchase Plan on September 25, 2020. Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options. /s/ Christopher Y. Chai, Attorney-in-Fact for David M. Goldstein 2020-09-28